Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (NASDAQ: MBRX) is trading at $0.57, about ₹55 at today's USD/INR rate, as of 28 Sep 2026, 4:00 PM ET, down 5.42% today. Indian residents can buy Moleculin Biotech from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$0.55
Today's high
$0.60
52 week low
$0.16
52 week high
$15.75
MBRX opened at $0.60, closed previously at $0.60, and has traded between $0.16 and $15.75 over the past 52 weeks.
About
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Key statistics
Avg. volume
1.15M
Market cap
$3.04M
P/E Ratio
-0.03
Price-to-sales ratio
0.00
Enterprise value
-$3.93M
Free cash flow yield
-835.11%
Debt-to-equity ratio
0.03
Return on equity
-816.56%
ROIC
-242.25%
Beta
1.92
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$0.00
Earnings per share
-$28.42
Free cash flow
-$22.73M
Net profit margin
0.00%
Gross margin
0.00%
EBITDA
-$33.47M
Revenue growth
—
Similar securities
This is not an investment recommendation
How to buy Moleculin Biotech from India
Indian residents can buy Moleculin Biotech shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Moleculin Biotech and place an order
Find Moleculin Biotech by name or by its ticker, MBRX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Moleculin Biotech trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Moleculin Biotech position in USD and INR. Moleculin Biotech pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Moleculin Biotech from India
Trading and taxes when buying Moleculin Biotech from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneMoleculin Biotech does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Moleculin Biotech stock?
Yes. Moleculin Biotech (MBRX) has been listed on NASDAQ since 2016, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Moleculin Biotech share cost in rupees?
One Moleculin Biotech share is $0.57 — about ₹55 at a USD/INR rate of 96.07 on 28 Sep 2026. Both the Moleculin Biotech price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Moleculin Biotech from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Moleculin Biotech?
Yes. One Moleculin Biotech share is $0.57, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Moleculin Biotech.
How are gains on Moleculin Biotech shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Moleculin Biotech price. Paasa issues a capital-gains statement for your return.
Does Moleculin Biotech pay a dividend?
No. Moleculin Biotech does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Moleculin Biotech from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Moleculin Biotech shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Moleculin Biotech shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Moleculin Biotech holding, its cost and its closing value.
How do I sell Moleculin Biotech and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.